Association of Ferritin Levels With Cytokine Release Syndrome in CAR T-Cell Therapy: A Systematic Review and Meta-Analysis.
Ranjit Sah, Abhinav Bhattarai, Sangam Shah et al.
✦ AI-curated · Sources linked
In 30 seconds
This systematic review and meta-analysis evaluated the role of ferritin levels in predicting cytokine release syndrome (CRS) in CAR T-cell therapy recipients. Analyzing data from 15 studies involving 1671 patients, the study found that elevated pre-infusion ferritin levels (≥400 ng/mL) were associated with higher CRS incidence and severity. Notably, pre-infusion ferritin levels were linked to worse progression-free survival (PFS) [HR: 2.18] and overall survival (OS) [HR: 2.97].
Key findings
- Elevated pre-infusion ferritin (≥400 ng/mL) linked to higher CRS incidence in 10 of 12 studies.
- Post-infusion ferritin consistently associated with CRS severity in all 9 studies.
- Pre-infusion ferritin levels significantly associated with worse PFS [HR: 2.18] and OS [HR: 2.97].
- Ferritin's predictive value is enhanced when integrated into multimarker models.
Why it matters
Understanding the role of ferritin in CRS can help clinicians better assess risk and tailor monitoring strategies for patients undergoing CAR T-cell therapy. While ferritin alone is not a definitive predictor, its integration with other biomarkers may improve risk stratification.